Henry Hui

Dr, BSc BMed PhD W.Aust., Early Career Researcher in the Translational Cancer Pathology Laboratory

  • The University of Western Australia (M504), 35 Stirling Highway,

    6009 Perth

    Australia

Calculated based on number of publications stored in Pure and citations from Scopus
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

I am a highly passionate early career research associate with an emerging international reputation in the development of advanced cell analysis technology and cutting-edge methodologies for both research and clinical applications. My work enables me to charter new frontiers in cytometry technology to advance knowledge and generate technical solutions to challenges in science, health and medicine. Since 2013, I have been key to the expansion of an award-winning, multi-disciplinary research team that leads the world in imaging flow cytometry powered diagnostic developments for haematological malignancies and blood-based disorders.

I am the co-inventor of the world-first “Immuno-flowFISH” method, a game-changing diagnostic technology. This invention enables precision assessment of blood cancers that vastly exceeds current research and clinical testing modalities. In 2018, I was awarded the awarded the highly prestigious ANSTO 2018 Eureka Prize for Innovative Use of Technology by the Australian Museum. My research has patented in many countries and my world-leading expertise has drawn investment and funding equivalent to $3.4M in value from industry partnerships, government grants and health-care organisations.

Currently, I have global multidisciplinary collaborative networks that intersect research, clinical and industry commercialization pipelines. This includes both industry leading medical technology corporations (Sysmex Corporation, Japan) and world-class diagnostic cancer centers (MD Anderson Cancer Centre, Texas USA and Addenbrooke’s Hospital, Cambridge, UK). I am currently leading the translational beta testing and commercialisation of immuno-flowFISH through this multi-disciplinary collaborative network to establish global adoption of this technology.

My long-term goal as a scientist is to lead the innovation, application, influence, education, engagement and outreach of medical research in both scientific and clinical domains, to advance knowledge and health globally.

Roles and responsibilities

2023- Australasian Cytometry Society (ACS) - Executive Secretary/council

2021 - 2022 Australasian Cytometry Society (ACS) – Advisory council 

2021– Research Associate, Translational Cancer Pathology Laboratory, UWA

2021– Marylou Ingram Scholar for the International Society for Advancement of Cytometry

2020– Australian Society for Medical Research WA (ASMR) State Committee member

2019 – 2021   Post-doctoral Research Scientist, Translational Cancer Pathology Laboratory, UWA

Funding overview

  • "Next-Generation Single Cell Diagnostics of Blood Cancers" Raine Priming Grants 2022 (Raine Medical Research Foundation). Chief Investigator A. Funds allocated: $$224,649 (2 years) 
  • "Precision Diagnostics for Blood Cancers" Future Health Research and Innovation Fund 2022 (Department of Health, Government of Western Australia). Chief Investigator C. Funds allocated: $499,632 (2 years)
  • "Developing a user-friendly machine learning enabled diagnostic tool for paediatric acute lymphoblastic leukaemia (ALL)" UWA Research Collaboration Awards (The University of Western Australia). Chief Investigator C. Funds allocated: $20,000 (1 year)
  • “Improving Survival in Childhood Leukaemia” Raine BrightSpark Research Collaboration Award (Raine Medical Research foundation). Chief Investigator A. Funds allocated: $29,864 (1 year)
  • Precision molecular diagnostics of single cells by imaging flow cytometry. National Health and Medical Research Council (NHRMC) Ideas grants. Chief Investigator C. Funds allocated: $875,110 (4 years)
  • Conquering Chronic Leukaemia in Children. The Channel 7 Telethon Trust. Chief Investigator C. Funds allocated:$124,000 (2 years)
  • Putting a new lens on childhood leukaemia. The Channel 7 Telethon Trust. Chief Investigator C. Funds allocated:$100,000 (2 years)
  • Development of the immuno-flowFISH method and analysis kit for the assessment of haematological and non- haematological cancers excluding plasma cell myeloma. Industry Sponsored Research Collaboration. Associate Investigator. Funds and instrument value allocated: $1.2 million (3 years)
  • Detecting high risk chromosomal aberrations in patients with myeloproliferative neoplasms using automated imaging flow cytometry for prognostication. Spinnaker Health Research Foundation. Associate Investigator. Funds allocated: $14,775 (1 year)
  • Australia-Japan Collaboration to Improve the Identification of Blood Cancers with Immuno-flowFISH. Foundation for Australia-Japan Studies. Associate Investigator. Funds allocated: $140,775 (2 years)
  • Automated imaging flow cytometry for disease monitoring and prognostication in myeloproliferative neoplasms. Faculty of Health and Medical Sciences Research Grants Scheme, UWA. Associate Investigator. Funds allocated: $99,000 (1 year)
  • Clinical validation of immuno-flowFISH for the assessment of plasma cell myeloma. SYSMEX Corporation Sponsored Research Collaboration. Associate Investigator. Funds allocated: $80,000 (3 years) 

Industrial relevance

I have industry funded collaborations to develop novel diagnostic tests and medical technology to advance scientific knowledge and human health. I lead or provide consultation (both interllectual and technincal input) on the development, testing, data review and comercialisation in these industry networks:

2020–  Research collaboration with undisclosed company

2018–  SYSMEX Corporation research collaboration

2019–  SCHOTT Minifab research collaboration

My work has been licensed and patented in multiple countries:

“Improvements in or relating to cell analysis” (WO/2019/079851) (PCT/AU2018/051148)

2020   USA (Standard) Patent US20200232019

2020   China (Standard) Patent CN111448324

2020   Europe (Standard) Patent EP2018870567

2018   Australia (Standard) PatentAU2018355889

Teaching overview

I have taught, trained, supervised and mentored undergraduates, Honours, Masters, PhD students and Clinical Fellows to achieve their ambitions in science and health. I continue to demonstrate and tutor in core Pathology and Biomedical sciences units from undergraduate to masters level (e.g. PATH 3309, MICR5542 & IMED 2201).

Engagement

Publicised, media releases/community engagement, impact and outreach

 

Community engagement

My responsibility as an emerging leader in science has enabled me to promote medical research and technological innovation to a broad audience. This includes engagement of community groups through medical research advocacy, fundraisers, cancer patient education and charity events:

2021   8 on the Point gala dinner for leukaemia research fundraising

2020– Australian Society for Medical Research WA (ASMR) State Committee

2020– Telethon family festivals

2020   Dato Tk Low Joondalup Resort Charity Golf Day 

2018   University of Western Australia Health Campus Open Day

2013 – 2021  University of Western Australia Open Day – School of Biomedical Sciences

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Industry keywords

  • Diagnostics
  • Medical Devices
  • Biotechnology
  • Digital Health

Research expertise keywords

  • Flow cytometry
  • Imaging flow cytometry
  • Immunofluorescence & imaging
  • Fluorescence In Situ Hybridization
  • Cancer Biology
  • Protocol optimisation
  • Cutting-edge method development
  • Diagnostic tests
  • Medical technology
  • Innovation & Automation
  • Blood & genetic based diagnostics
  • Chronic Lymphocytic Leukaemia (CLL)
  • Multiple myeloma
  • Pediatric Leukaemia
  • Acute Lymphoblastic Leukaemia (ALL)
  • Intergrated platforms & systems
  • Automation

Fingerprint

Dive into the research topics where Henry Hui is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Network

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or